about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

HIV, pneu­mo­coc­cal — and what? Mer­ck­'s un­ex­pect­ed pipeline high­light ex­cites a lit­tle biotech

6 years ago
R&D

'Our lega­cy mat­ter­s': Mer­ck maps out Keytru­da king­dom while spot­light­ing ad­vances in vac­cines, hos­pi­tal care

6 years ago
R&D
Pharma

In­vestors pony up $476M for the lat­est round of biotech IPOs to hit the Street

6 years ago
Financing

Who’s next in line to suc­ceed Ken Fra­zier as CEO of the Keytru­da-blessed Mer­ck?

6 years ago
People

Wood­ford braces po­lit­i­cal storm as UK fi­nan­cial reg­u­la­tors scru­ti­nize fund sus­pen­sion

6 years ago
People
Financing

Iron­wood, Al­ler­gan add a slate of PhI­I­Ib da­ta to its Linzess pitch for physi­cians, pa­tients

6 years ago
Pharma

Step­ping on Roche's toes, Mer­ck cuts in­to SCLC niche with third-line Keytru­da OK

6 years ago
Pharma

Roche fields first ap­proval for Ro­z­lytrek in the run-up to a show­down with Bay­er, Pfiz­er

6 years ago
R&D

As­traZeneca spin­out Viela Bio pock­ets $75M on its way to BLA for au­toim­mune drug

6 years ago
R&D

As Bris­tol-My­ers/Cel­gene tie up loose ends, BeiGene pock­ets $150M from PD-1 breakup

6 years ago
Deals
China

Philadel­phia cham­pi­ons life sci­ences 'co-work­ing,' re­viv­ing for­mer GSK cam­pus in $500M makeover

6 years ago
Startups

Chi-Med cuts su­r­u­fa­tinib PhI­II short; FDA green­lights Her­ceptin copy­cat from Am­gen, Al­ler­gan

6 years ago
News Briefing

BeiGene touts 'en­cour­ag­ing' re­sponse rates as the Chi­nese biotech mounts chal­lenge to BTK, PD-1 lead­ers

6 years ago
R&D

GSK's Bar­ron joins hands with Doud­na, Weiss­man to de­ploy CRISPR tech in drug dis­cov­ery

6 years ago
Deals
Discovery

Adding mar­quee in­vestors, Black­Thorn bags $76M to back an AI-dri­ven strat­e­gy for pre­ci­sion neu­ro med­i­cine

6 years ago
Financing
Startups

Fol­low­ing CAR-T pi­o­neer­s' foot­steps, Tes­sa launch­es Chi­na JV in $120M deal

6 years ago
Financing
China

Tech con­glom­er­ate buys Me­di­da­ta for $5.7B; Alexan­dria teams up with Co­lum­bia for sec­ond Launch­Labs; So­bi all in on ...

6 years ago
News Briefing

Or­biMed-backed Pre­lude Ther­a­peu­tics rais­es $60M to tack­le re­sis­tance to can­cer treat­ments

6 years ago
Financing
Startups

Plagued by de­lays, As­traZeneca HQ costs soar to £750M as it edges to­ward 2020 com­ple­tion

6 years ago
Pharma

Syn­log­ic, Gink­go ex­pand mi­cro­bial dis­cov­ery pact, throw­ing $80M in­vest­ment in­to the mix

6 years ago
R&D

Search­ing for the next block­buster to fol­low Darza­lex, J&J finds a $150M an­ti-CD38 drug from part­ner Gen­mab

6 years ago
R&D

Mer­ck grows Keytru­da in­di­ca­tions with head and neck can­cer ap­proval

6 years ago
Pharma

Russ­ian sci­en­tist plans to one-up Jiankui He in cre­at­ing his own CRISPR ba­bies — Na­ture

6 years ago
Discovery

In a boost to Rit­ux­an fran­chise, Roche nabs quick ap­proval for po­latuzum­ab ve­dotin

6 years ago
Pharma
First page Previous page 96979899100101102 Next page Last page
A service from the Financial Times